Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

PURPOSE: The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors. PATIENTS AND METH...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Abu-Sbeih, Hamzah, Faleck, David M., Ricciuti, Biagio, Mendelsohn, Robin B., Naqash, Abdul R., Cohen, Justine V., Sellers, Maclean C., Balaji, Aanika, Ben-Betzalel, Guy, Hajir, Ibraheim, Zhang, Jiajia, Awad, Mark M., Leonardi, Giulia C., Johnson, Douglas B., Pinato, David J., Owen, Dwight H., Weiss, Sarah A., Lamberti, Giuseppe, Lythgoe, Mark P., Manuzzi, Lisa, Arnold, Christina, Qiao, Wei, Naidoo, Jarushka, Markel, Gal, Powell, Nick, Yeung, Sai-Ching J., Sharon, Elad, Dougan, Michael, Wang, Yinghong
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7030892/
https://ncbi.nlm.nih.gov/pubmed/31800340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01674
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados